On March 26, 2012, the U.S. Department of Health & Human Services Office of Inspector General (the “OIG”) published a report summarizing a February 23, 2012roundtable meeting between the OIG and compliance professionals from twenty-three pharmaceutical manufacturers. The compliance officers and other professionals attending the meeting all represented companies currently operating under Corporate Integrity Agreements (or “CIAs”). CIAs are generally negotiated between a company and the government in connection with settling various types of federal ...
Blog Editors
Recent Updates
- Georgia & North Dakota: More State Judges Question the Constitutionality of Abortion Bans
- OCR Withdraws Appeal of District Court Order Declaring Unlawful and Vacating the “Proscribed Combination” Portion of Its HIPAA Online Tracking Technologies Guidance
- As the Window for Comments Closes on ONC/ASTP’s HTI-2 Proposed Rule: What’s in HTI-2 and What Does It Mean for You?
- Unpacking Averages: Assessing FDA’s Postmarket Surveillance Under Section 522
- Video: New State Legislation Increases Oversight of Health Care Transactions – Thought Leaders in Health Law